Images List Premium Download Classic

Restenosis

Restenosis-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Scaffold with drug coating for preventing and treating restenosis and preparation method thereof
Xiyuan Hospital Of China Academy Of Chinese Medical Sciences
August 03, 2017 - N°20170216497

Disclosed is a stent with a drug coating for preventing and treating restenosis, comprising, a stent and a drug coating covering the surface of the stent. The active ingredients in the drug coating are guaiane sesquiterpene compounds p1, p2 and p3. P1 is zedoalactone b, p2 is a stereoisomer of p1, and p3 is zedoarondiol. Compared with an existing sirolimus ...
Compounds and methods for modulating vascular injury
The Brigham And Women's Hospital, Inc.
August 03, 2017 - N°20170216238

Methods of modulating healing response to vascular injury and/or vascular scarring in a subject are provided. As such, aspects of the disclosure relate to the use of pro-resolving lipid mediators to modulate inflammation and/or restenosis of a vascular wall. Another aspect of the disclosure relates to the use of pro-resolving lipid mediators to modulate a biological activity of ...
Small molecule inhibitors of stat3 with anti-tumor activity
University Of Central Florida Research Foundation.
July 20, 2017 - N°20170202795

The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of stat3 signaling, stat3 dimerization, stat3-dna binding, stat5-dna binding, and/or aberrant cell growth in vitro or in vivo, e. G., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but ...
Restenosis Patent Pack
Download + patent application PDFs
Restenosis Patent Applications
Download + Restenosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Restenosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Stent for inhibiting restenosis and stimulating reendothelialization prepared by femtosecond laser processing and method of ...
Jeonnam Technopark
June 29, 2017 - N°20170182227

Provided are a stent in which a surface of a stent strut is treated by femtosecond laser radiation and is modified by a natural polymer and a method of preparing the stent. The stent and the preparing method may inhibit restenosis and stimulate reendothelialization.
Drug-eluting medical device
Invatec Technology Center Gmbh
June 22, 2017 - N°20170173220

The present invention relates to a drug-eluting medical device, in particular a balloon for angioplasty catheters with drug elution to prevent the restenosis of the vessel subjected to angioplasty. More particularly, the present invention relates to a catheter balloon completely or partially coated with paclitaxel in hydrated crystalline form or in hydrated solvated crystalline form, having an immediate release and ...
Trka kinase inhibitors, compositions and methods thereof
Merck Sharp & Dohme Corp.
June 08, 2017 - N°20170158698

The present invention is directed to substituted five membered heteroaryl benzamide compounds of formula (i) (formula (i)) which are tropomyosin-related kinase (trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal ...
Restenosis Patent Pack
Download + patent application PDFs
Restenosis Patent Applications
Download + Restenosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Restenosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Coating composition and medical device
Legochem Biosciences,inc.
May 25, 2017 - N°20170143663

A coating composition for drug-eluting medical devices, which enables a medical device to be delivered to a target tissue for the purpose of treating an affected blood vessel part such as restenosis, without easy separation of a drug from the medical device during the delivery process is provided. The coating composition for drug-eluting medical devices contains a water-insoluble drug and ...
Balloon angioplasty catheter coating to encourage vessel repair and further reduce restenosis
Angioscore, Inc.
May 18, 2017 - N°20170136219

A method for treating a target vascular portion of a subject including: providing an angioplasty balloon system including a balloon carrying a first therapeutic agent and a second therapeutic agent on a surface of the balloon, wherein the first therapeutic agent is an anti-proliferative or anti-mitotic agent and the second therapeutic agent is a drug that aids in vascular healing ...
Trka kinase inhibitors, compositions and methods thereof
Msd R & D (china) Co., Ltd.
April 27, 2017 - N°20170114071

The present invention is directed to six membered heteroaryl benzamide compounds of formula (i), which are tropomyosin-related kinase (trk) family protein pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (ngf) receptor trka.
Trka kinase inhibitors, compositions and methods thereof
Merck Sharp & Dohme Corp.
April 27, 2017 - N°20170114056

The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula (i) which are tropomyosin-related kinase (trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve ...
Trka kinase inhibitors, compositions and methods thereof
Merck Sharp & Dohme Corp.
April 20, 2017 - N°20170107204

The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula (i) which are tropomyosin-related kinase (trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve ...
Devices for controlling magnetic nanoparticles to treat fluid obstructions
Pulse Therapeutics, Inc.
April 06, 2017 - N°20170095675

A system for the physical manipulation of free magnetic rotors in a circulatory system using a remotely placed magnetic field-generating stator is provided. In one embodiment, the invention relates to the control of magnetic particles in a fluid medium using permanent magnet-based or electromagnetic field-generating stator sources. Such a system can be useful for increasing the diffusion of therapeutic agents ...
Methods and apparatus for stenting comprising enhanced embolic protection coupled with improved protections against restenosis ...
Abbott Laboratories Vascular Enterprises Limited
March 30, 2017 - N°20170086965

Apparatus and methods for stenting are provided comprising a stent attached to a porous biocompatible material that is permeable to endothelial cell ingrowth, but impermeable to release of emboli of predetermined size. Preferred stent designs are provided, as well as preferred manufacturing techniques. Apparatus and methods are also provided for use at a vessel branching. Moreover, embodiments of the present ...
Restenosis Patent Pack
Download + patent application PDFs
Restenosis Patent Applications
Download + Restenosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Restenosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Substituted pyridazines as prostacyclin receptor modulators
Arena Pharmaceuticals, Inc.
March 02, 2017 - N°20170057931

Cyclohexane derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood ...
Variants of c-type natriuretic peptide
Biomarin Pharmaceutical Inc.
February 23, 2017 - N°20170051033

The present disclosure provides variants of c-type natriuretic peptide (cnp), pharmaceutical compositions comprising cnp variants, and methods of making cnp variants. The cnp variants are useful as therapeutic agents for the treatment of diseases responsive to cnp, including but not limited to bone-related disorders, such as skeletal dysplasias (e. G., achondroplasia), and vascular smooth muscle disorders (e. G., restenosis and ...
3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
Biomarin Pharmaceutical Inc.
February 23, 2017 - N°20170050942

(wherein r1, r2, r3, r4, r5, r6, r7, x, y and z are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as modulators of the ccr2 and/or ccr5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, ...
Selective inhibitors of c-fos and their antiproliferative properties
Centre National De La Recherche Scientifique(cnrs)
February 02, 2017 - N°20170029487

Selective inhibitor of c-fos and their antiproliferative properties the invention relates to selective inhibitor of c-fos for use in the prevention and/or treatment of cancers and restenosis.
5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative
Daiichi Sankyo Company, Limited
December 29, 2016 - N°20160376267

A compound represented by the general formula (i) or a pharmacologically acceptable salt thereof has an excellent lcat-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke ...
Drug-eluting coatings on poly(dl-lactide)-based scaffolds
Abbott Cardiovascular Systems Inc.
December 29, 2016 - N°20160374838

Stents including a poly(d,l-lactide)(pdlla)-based scaffold and pdlla based therapeutic layer are disclosed. The pdlla based scaffold may be amorphous and may include a primer layer. Methods of applying the pdlla-based coating to the scaffold are disclosed with solvent processing methods using a solvent blend are also disclosed. Methods of removing residual solvent from a pdlla-base coating ...
Activators of cxcr3 for the treatment of angiopathies of the eye
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
December 15, 2016 - N°20160361387

The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of c-x-c chemokine receptor 3 (cxcr3). In some embodiments, the activator of cxcr3 is interferon-γ-inducible 10 kda protein (ip-10) or a fragment or variant thereof, such as a fragment comprising or consisting ...
Hybrid stent and method of making
Abbott Cardiovascular Systems Inc.
December 01, 2016 - N°20160346102

A stent is formed by encasing or encapsulating metallic rings in an inner polymeric layer and an outer polymeric layer. At least one polymer link connects adjacent metallic rings. The stent is drug loaded with one or more therapeutic agent or drug, for example, to reduce the likelihood of the development of restenosis in the coronary arteries. The inner and ...
Loading